Pharmaceutical

Emergent to sell US sterile manufacturing facility to Bora

Emergent BioSolutions has agreed to divest its sterile manufacturing facility in Baltimore-Camden, Maryland, to Bora Pharmaceuticals.

Jun 22, 2024 - 04:00
Emergent to sell US sterile manufacturing facility to Bora
Emergent BioSolutions has agreed to divest its sterile manufacturing facility in Baltimore-Camden, Maryland, to Bora Pharmaceuticals.
Read the original article

Tags:

Previous Article

South Korea seeks to accelerate drug reimbursement administration process

Next Article

Johnson & Johnson seeks FDA approval for Tremfya for Crohn’s disease

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Was CAR-T therapy a bystander or driver of lymphoma? Researchers examine first published case

STAT+: Was CAR-T therapy a bystander or driver of lymph...

Dec 9, 2023

Peptic Ulcers drugs in development, 2023

Nov 30, 2023

STAT+: Pharmalittle: How 98 days may cost J&J big bucks; Walgreens CEO departs

STAT+: Pharmalittle: How 98 days may cost J&J big bucks...

Sep 2, 2023